Showing results (101-110 of 106) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Diabetes, Obesity & Metabolism|September 7, 2020
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational studyKåre I Birkeland, Johan Bodegard, Amitava Banerjee, et al.Diabetes, Obesity & Metabolism|May 5, 2020
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort studyKåre I Birkeland, Johan Bodegard, Jan W Eriksson, et al.Diabetes, Obesity & Metabolism|March 24, 2022
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countriesAnna Norhammar, Johan Bodegard, Jan W Eriksson, et al.The Lancet. Diabetes & Endocrinology|June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.Cardiovascular Diabetology|August 1, 2021
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataKamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, et al.ESC Heart Failure|July 23, 2022
Impact analysis of heart failure across European countries: an ESC-HFA position paperGiuseppe M C Rosano, Petar Seferovic, Gianluigi Savarese, et al.Pageof 11